I have thought for a long while now that Astex would be an interesting target for Celegene but it could never happen because the FTC would never allow it. However once Dacogen and Vidaza go generic this impediment goes away. Its also nice timing with more data availabel in the coming months on S110. .
Just a thought but who knows the MDS/AML space better than Celgene and could reap full benefits from S110 if turns out to be the super drug we all hope it will
Hey Man, nice to have you back. What kind of premium do we want, lol. I will take $8 and run for the hills. That would be a roughly $750M for Celgene. For that they get a variety of things including cash, 6 Phase 2 trials, 5 partner-funded products in Phase 1 clinical development and Mancuso's expertise! I like the idea Bat. Makes a whole lot more sense now than about 6-9 months ago.